1. Home
  2. FNWB vs IMUX Comparison

FNWB vs IMUX Comparison

Compare FNWB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Northwest Bancorp

FNWB

First Northwest Bancorp

HOLD

Current Price

$8.64

Market Cap

79.8M

Sector

Finance

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$1.16

Market Cap

75.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNWB
IMUX
Founded
1923
2016
Country
United States
United States
Employees
N/A
66
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.8M
75.2M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
FNWB
IMUX
Price
$8.64
$1.16
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$13.50
$4.25
AVG Volume (30 Days)
28.0K
3.0M
Earning Date
04-23-2026
02-26-2026
Dividend Yield
0.81%
N/A
EPS Growth
36.00
38.00
EPS
N/A
N/A
Revenue
$176,000.00
N/A
Revenue This Year
$19.24
N/A
Revenue Next Year
$8.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.05
$0.51
52 Week High
$10.98
$1.51

Technical Indicators

Market Signals
Indicator
FNWB
IMUX
Relative Strength Index (RSI) 21.39 55.82
Support Level $8.16 $0.64
Resistance Level $9.00 $1.17
Average True Range (ATR) 0.29 0.13
MACD -0.05 -0.02
Stochastic Oscillator 2.88 33.55

Price Performance

Historical Comparison
FNWB
IMUX

About FNWB First Northwest Bancorp

First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: